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Abstract Obesity has become a serious public health
problem that has stimulated primordial and primary pre-
vention efforts, and a triad of management options (lifestyle,
pharmacotherapy, and surgical interventions). A growing
body of evidence supports the need for a multi-pronged,
clinic-based approach that leverages the synergy between
pharmaceutical and lifestyle modification. Recent US policy
changes—namely, the passage of the Patient Protection and
Affordable Care Act coupledwith recognition of obesity as a
disease by the American Medical Association—suggest that
financial incentives and attitudes towards obesity manage-
ment are changing. This paradigm shift has implications for
current and future obesity pharmacotherapy. However, bar-
riers to pharmacotherapy utilization include patient and
physician perceptions of modest efficacy, historical safety
issues, regulatory obstacles, and lack of reimbursement. The
shifting attitudes and challenges associated not only with a
multi-payer system, but also the lack of clearly defined cross-
payer reimbursement strategies, prompted a survey to de-
termine coverage for obesity treatment. Participants indi-
cated that federal/state mandates and growth of quality-
driven healthcare initiatives will eventually drive wider
pharmacotherapy reimbursement within 1–5 years. There
are signs that federal/state programs are already moving to-
wards reimbursement by improving quality measures to
track obesity outcomes and reduce costs. Future research on
clinical and economic outcomes of combination weight-
management programs coupled with innovative approaches
(e.g., eHealth) in the real-world setting that demonstrate
value to patients, healthcare providers, payers, and em-
ployers will help reshape obesity management by reducing
barriers and broadening reimbursement coverage for anti-
obesity pharmacotherapy.
Key Points for Decision Makers
Obesity pharmaceuticals have historically suffered
from drug-related tolerability/safety issues; however,
heightened scrutiny during drug development and
the mandatory inclusion of long-term cardiovascular
safety studies has led to a growing number of safer
treatment options.
There are multiple barriers to the widespread
adoption of obesity pharmaceuticals in medical
practice: patient perceptions and treatment
expectations, lack of resources to address the full
range of obesity lifestyle and environmental
determinants, and limited health insurance coverage
for treatment and medication.
1 Introduction
Obesity—defined by the US National Heart Lung Blood
Institute (NHLBI) as a body mass index (BMI) C 30.0 kg/
m2 [1]—has become a serious global public health problem
disproportionately affecting developed countries [2, 3] and
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reaching epidemic proportions in the USA [4–6]. Efforts to
limit the spread of obesity [7] have addressed both pre-
vention and treatment. Preventive approaches have en-
compassed lifestyle modification interventions (e.g., diet
and exercise) [8, 9], public education on nutrition [10], and
efforts to increase access to nutritious food options [11, 12]
and promote healthy eating (including regulation of the
food industry [13, 14]). In addition, treatment efforts have
included a triad of long-term therapeutic options: lifestyle
modification such as behavioral therapy (BT), pharma-
cotherapy, and surgical treatment [15, 16].
Preventive efforts have seen some success [17–19], but
not enough [20] to reverse the increasing obesity incidence
in developed countries [3]. Clinical management efforts also
face substantial difficulties, despite promising clinical trial
results. Clinical trials of behavior and/or lifestyle modifi-
cation have shown modest weight loss and beneficial effects
on glycemic control, cardiovascular risk factors, and de-
velopment of type 2 diabetes mellitus [21–26], but these
findings have been difficult to translate into primary care
settings for a number of reasons. First, these interventions
are resource-intensive and require specially trained per-
sonnel such as behavioral psychologists, dietitians, and
health coaches. Second, they often involve one-on-one or
group sessions that require clinic space as well as repeat and
frequent clinic visits, which, taken together, are financially
unsustainable given the lack of commercial insurance re-
imbursement [27]. Third, physicians ably manage obesity-
related co-morbid conditions, cardiovascular risk factors,
and mechanical complications including obstructive sleep
apnea [28, 29]. While aware of the need to address obesity,
physicians lack adequate tools or support systems and,
consequently, rarely assess the goals of treatment or provide
motivational support or referral to weight-management
counseling [30]. The US Patient Protection and Affordable
Care Act (PPACA) [31] emphasizes the importance of
prevention in primary care as a way to improve outcomes
and reduce cost. However, without additional tools, and
confronted with competing priorities, physician efforts
against obesity remain modest. Recent data suggest that
preventive health efforts have started to flatten the childhood
obesity curves, though the opposite is true for rates of ex-
treme obesity [32]. In addition, the modest degrees of weight
loss observed with behavioral interventions have led to a
rapidly growing specialization in surgical obesity treatment
programs. An analysis by the Agency for Healthcare Re-
search and Quality showed that the number of bariatric
surgeries, which is generally reserved for highly motivated
patients with a BMI cutpoint of C40 or C35 kg/m2 with an
obesity-related co-morbid condition [1], grew ninefold from
1998 to 2004 [33]; further, the use of lap-band surgery was
recently expanded by the US Food and Drug Administration
(FDA) to include patients with a BMI of C30.0 kg/m2 with
an existing condition related to their obesity [34]. A review
of the different surgical treatment options is beyond the
scope of this paper, but bariatric surgery has the demon-
strated benefits of rapid and substantial weight loss and
clinically important improvements in some biomarkers of
co-morbid disease [35–37]. Unfortunately, recent studies of
long-term outcomes with bariatric surgery show weight loss
is sometimes not sustained; recidivism after surgery can be
significant [38, 39]; and reoperation can be necessary with
an attendant increase in operative and post-operative mor-
bidity and mortality [40].
The option of obesity pharmacotherapy, coupled with
new and advanced minimal-contact behavioral modifica-
tion and lifestyle change programs [41], represent another
treatment option. Pharmacotherapy is recommended as an
adjunct to lifestyle modification in obese individuals with a
BMI of C30.0, or C27 kg/m2 with an obesity-related co-
morbid condition [1], and recent results support that
combining pharmacotherapy with lifestyle intervention
leads to greater weight loss than either therapy alone [42].
While pharmacotherapy-assisted weight loss is also subject
to recidivism, evidence shows that weight regain may be
slowed or prevented with continued medication use [1].
The economic consequences of obesity and its associ-
ated co-morbidities are staggering and 2008 US estimates
suggest that annual aggregate medical spending may be as
high as $US147 billion per year [43]. Efforts to curb
healthcare spending in the USA have focused on obesity as
an upstream driver of multiple chronic diseases and support
the case for a comprehensive, multifaceted approach to the
obesity epidemic. At an individual patient level, little data
exist to support the effectiveness of non-surgical treatment
on healthcare cost; however, a recent study from the
University of Michigan reported promising data on a real-
world treatment that reduced healthcare utilization and cost
in as little as 1 year [44].
It is within the context of real-world observational
analyses afforded by the vertical integration of the US
healthcare system and the alignment of stakeholders on
pay-for-performance for improved outcomes and cost
savings that we believe the cost benefit of pharmacotherapy
will be demonstrated. This review provides an update and
perspective on the evolving healthcare determinants,
which, when coupled with obesity pharmacotherapy cost
benefit, may drive future insurance reimbursement and
greater patient access to treatment.
2 Previous Anti-Obesity Drugs and Implications
for Current Pharmacologic Treatment
Although the first anti-obesity drug desoxyephedrine (or
methamphetamine) was approved by the FDA in 1947, and
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the most commonly prescribed medication phentermine
was approved in 1959, sales of drugs with this indication
did not accelerate until the early 1990s [45]. During this
period, obesity prevalence rapidly increased [46] and the
contribution of obesity to the development or worsening of
a large number of medical conditions was better recognized
[47, 48]. Yet, the adverse effects associated with these
early drugs were considered too dangerous or undesirable
for long-term use, thus limiting physician treatment options
[45]. The obesity drug combination of fenfluramine/phen-
termine (known as fen-phen) was serendipitously discov-
ered through clinical trial and error. Fen-phen had potent
anorectic effects and consequently gained popularity in the
early 1990s, reaching a peak of 18 million prescriptions in
1996 [49] despite the absence of FDA approval [50].
Fenfluramine (with its derivative dexfenfluramine or Re-
duxTM) was withdrawn from use in the USA in 1997 amid
a major safety signal from reports of increased rates of
valvular heart damage, primary pulmonary hypertension,
and other severe complications associated with long-term
use [51]. After the fen-phen experience, sibutramine en-
tered the anti-obesity field in 1997, orlistat in 1999, and
rimonabant was approved for use in the European Union in
2006. While showing some initial success, concerns about
the weak efficacy of some of these agents, disruptive ad-
verse events in the case of orlistat (e.g., bloating, flatu-
lence, and diarrhea), cardiovascular risks with sibutramine
(leading to its subsequent withdrawal in 2010), and de-
pressive/suicidal reactions with rimonabant (withdrawn in
2009) ultimately led to a steady decline in weight-loss drug
sales. Consequently, global revenue of anti-obesity drugs
went from an estimated $US870 million in 2000 [52] to
$US677 million in 2009 [53], then to $US359 million in
2011 [54].
Since 2012, three anti-obesity drugs have received
regulatory approval in the USA (lorcaserin [55], phenter-
mine/topiramate combination [56], and bupropion SR [-
sustained-release formulation]/naltrexone SR combination
[57]) after additional regulatory demands and delays [58].
These anti-obesity pharmacotherapy options along with
orlistat remain available for long-term treatment; however,
phentermine is currently the most commonly prescribed
anorectic agent despite FDA labeling that limits use to
3 months or less.
The recent successful approval of three new anti-obesity
agents belies a number of barriers. First, drug development is
both costly and risky. Between 1993 and 1994, only 7.9 % of
all compounds first tested in humans received regulatory
approval [59], and $US0.8–1.2 billion was spent on average
for each new drug development [60–63]. While the prob-
ability of regulatory approval is estimated to be 19 % for
applications across drug classes [59], the historical success
rate (1993–2004) for medications affecting metabolism/the
gastrointestinal system and the central nervous system has
been much lower—3.3–3.8 % [59]—and reflects the diffi-
culty in finding targets that are free from metabolic redun-
dancy and safety issues. Nonetheless, regulatory approval is
particularly difficult to obtain for anti-obesity drugs [64, 65],
and the FDA now requires the results of a long-term car-
diovascular outcomes trial in the applications.
On top of drug development and approval barriers,
pharmaceutical companies have largely relied on patient
and physician acceptance of out-of-pocket reimbursement.
Low rates of insurance reimbursement remain a major
barrier, despite clinical guidelines recommending the use
of anti-obesity drugs [15, 66]. Insurance coverage has
generally been confined to employer-sponsored insurance
plans with no government reimbursement [67, 68]. Finally,
the lack of insurance has precluded long-term treatment
and led to reluctance to prescribe due to the belief that
weight regain post short-term treatment is likely. These
treatment barriers taken together with historical safety is-
sues have led providers to resist prescribing anti-obesity
medications [68, 69]. However, the multiple factors af-
fecting anti-obesity medication use have not seemed to
slow the influence from pharmaceutical companies, and
pipelines remain robust.
3 Recent Policy Developments May Presage Change
Since the withdrawal of sibutramine from the list of ap-
proved drugs for the treatment of obesity in 2010 [70], two
significant developments in US healthcare policy have
occurred, with important implications for the treatment of
obesity. First, the PPACA, adopted into law in 2010 [31],
strengthened the trend toward financial incentives for im-
proved care and preventive health measures, including the
prevention of obesity [71]. Two federal initiatives within
PPACA created Accountable Care Organizations (ACOs),
particularly the Medicare Shared Savings Program (MSSP)
in which individual and organizational healthcare providers
assume financial risk for a defined population of elderly
and disabled Americans. MSSP ACOs expect to benefit
from the shared savings that result from improved quality
performance measures [72]. Among the MSSP ACO
quality measures are BMI screening and follow-up, which
are expected to affect more than 4 million Medicare
beneficiaries. The same BMI quality measures are reported
to the National Committee on Quality Assurance (NCQA)
as part of their ACO accreditation program. As opposed to
self-insured providers, MSSP ACOs have required inte-
gration and employment of providers within coordinated
hospital systems (i.e., vertical healthcare) to achieve im-
provements in healthcare quality and secondarily reduce
costs. In parallel with government-sponsored ACOs,
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commercially insured ACOs have arisen within these sys-
tems, which now number close to 1,000.
In addition to quality measures, incentive programs were
provided by the Health Information Technology for Eco-
nomic andClinical HealthAct (HITECHAct) of 2009 [73] to
help integrate patient information from acute care visits,
ambulatory encounters, pharmacy, laboratory, imaging, and
even genetic and other relevant data through the implemen-
tation of efficient Electronic Health Records (EHR) systems.
These measures are intended to improve patient safety and
outcomes and reduce the costs associated with uncoordinat-
ed, unnecessary, or duplicative care. By 2015, incentives for
EHR will require meaningful use of data to improve
population health [74], creating an ideal environment for the
care integration required for effective obesity treatment.
The second significant development came in June of
2013, when the American Medical Association (AMA)
recognized obesity as a complex disease [75, 76] requiring a
range of interventions for effective treatment. Other orga-
nizations were more tentative in their approach: new
cholesterol and obesity guidelines issued by the American
Heart Association, the American College of Cardiology, and
The Obesity Society [1] were not endorsed by the American
Association of Clinical Endocrinologists (AACE) because
the guidelines ‘‘fail to classify obesity as a disease and
continue the paradigm of BMI-centric risk stratification,
both of which are contrary to recently stated AACE posi-
tions.Moreover, the guidelines do not include any of the new
FDA-approved pharmacologic agents to assist with weight
loss’’ [77]. Regardless, recognition of the complexity of
obesity, its multifactorial etiology, and its contribution to
increased morbidity and mortality [78] should encourage
prevention programs and treatment, and increase access to a
range of treatment options [79]. The goal will be a concerted
effort by patients, physicians, and payers to address and
manage the current obesity epidemic [80, 81].
Together, these policy developments increase incentives
for stakeholders to manage obesity more proactively, in-
cluding through pharmacotherapy, if incremental anti-
obesity benefit can be provided with appropriate levels of
safety. This assumption may not be unlike past health
policies focused on chronic health conditions (e.g., excise
taxes that raised the price of cigarettes, pharmacological
treatment/behavioral support for smoking cessation, indoor
smoking bans) that presaged a significant decline in
smoking in the USA [82].
4 Patient and Physician Perspectives: Challenge
of Market Demand
Patient and physician views on obesity present a potential
barrier to more systematic use and reimbursement of
pharmacotherapy. Patients have historically pursued a num-
ber of self-management options for weight loss, including
popular diets and commercial programs [83], or other over-
the-counter options such as dietary/herbal supplements [84].
Past treatment patterns also indicate that patients take drugs
seasonally [85], and do not recognize a role for pharmaco-
logic therapy in maintenance of weight loss. While behav-
ioral and pharmacologic treatments have typically yielded a
clinically beneficial [86–89] 5–10 % weight loss, patients
frequently expect much greater weight loss [90]. In part, their
expectations are conditionedby their desire to return to a prior
baseline weight, reflecting an under-appreciation of the so-
cial, environmental, and metabolic barriers that make weight
loss difficult [90]. Hence, when coupled with lack of insur-
ance reimbursement, there is little long-term adherence to
current anti-obesity pharmaceuticals [91].
Physicians’ perceptions and views of obesity also have
affected treatment patterns for obesity. While there are
limited data on physician treatment choices in the primary
care setting, surveys have found that physicians recom-
mend counseling for weight loss, including generalized
advice on physical activity and diet [92, 93]. Although
92 % of respondents in a 2003 study of primary care
physicians viewed obesity as a chronic condition, a much
smaller percentage (26 %) felt that anti-obesity medicines
should be used long-term [94]. In a 2007 survey of family
physicians in Central New York, respondents typically
viewed obesity as a chronic disease [95] and were
relatively well aware that a 10 % decrease in total body
weight may have significant impact on obesity-related co-
morbidities, such as hypertension, diabetes, and heart dis-
ease [96]. Physicians have traditionally been more
comfortable addressing obesity-related co-morbidities [93,
97–99], rather than addressing obesity treatment options,
largely because of lack of training in prescribing specific
nutrition and physical activity regimens [100]. Given the
recent US approval of long-term anti-obesity pharma-
cotherapies, eHealth options [101], and advances in self-
monitoring technologies [102], it will soon be possible to
relieve physicians of some of the barriers of treatment. In
addition, there is a need for better treatment guidelines,
tools for screening, and better coordination of care, in-
cluding alignment with public health efforts [95]. These are
the very issues that the PPACA and the AMA declaration
of the obesity disease model are currently attempting to
address through policy changes focused on obesity.
5 Payer and Employer Perspectives: Challenges
of Reimbursement
Provider reimbursement for surgical management of ex-
treme obesity (BMI C40 kg/m2) has not only evolved but
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also dramatically increased over the last 10–15 years. This
growth has been fueled by multiple factors, including im-
proved procedures, weight loss, outcomes, and the recog-
nition of extreme obesity as the fastest growing segment of
the obese population [103]. While bariatric surgery can
significantly improve weight-related co-morbid disease and
consequently be life-saving, concerns about the financial
burden remain, with average cost estimates approximating
$US20,000 among an eligible US population of 14.5 mil-
lion adults [103]. In the fragmented US payer environment,
with private, government, and employer-based reimburse-
ment systems, and patient movement between these sys-
tems (average turnover of 2–3 years), there has been
reluctance to pay for bariatric surgery and obesity phar-
macotherapy, despite evidence suggesting long-term health
benefits and cost effectiveness [103, 104]. The passage of
the PPACA and government mandates, such as increased
reimbursement for lifestyle/behavioral approaches to obe-
sity treatment, attempt to bypass barriers and may help
drive the liberalization of physician treatment reimburse-
ment as well as increased willingness to prescribe anti-
obesity medication [68, 69]. Additionally, with adequate
medication reimbursement, patients stay on anti-obesity
drugs longer, see their doctor more often, and lose more
weight [105]. The recent AMA declaration of obesity as a
disease has also led to prominent policy changes. Recently,
the US Office of Personnel Management indicated that
federal employees’ health benefit plans are not permitted to
exclude coverage of newly approved obesity medications
on the basis that obesity is a ‘‘cosmetic’’ or ‘‘lifestyle’’
issue; this policy goes into effect in 2015 and will impact
2.7 million federal employees and their beneficiaries [106,
107].
Based on the paucity of data on obesity pharma-
cotherapy reimbursement across non-governmental payers
and the rapidly changing US attitudes toward obesity
treatment reimbursement, a survey was undertaken in
November 2013, which was funded by Takeda Pharma-
ceuticals USA, and executed by Strategic Healthcare
Alliance (SHA). The goal of the survey was to determine
the current and future plans of healthcare funding entities
(employers and private insurance payers) with regard to
coverage for obesity treatment. The findings of the study
described here provide general direction on this topic, but
are based on qualitative research and may not be gener-
alizable to the broader population of payers and healthcare
systems. Three 90-min group discussions were held with
senior-level representatives from different stakeholder
audiences: commercial Managed Care insurance Organi-
zations (MCOs; n = 9), Pharmacy Benefit Managers
(PBMs; n = 9), and healthcare providers from Integrated
Healthcare Systems (IHSs; n = 10)—all of whom share
risk around cost and healthcare outcomes with govern-
ment and/or commercial payers. SHA provided a list of
six levers for respondents to rank by importance (Fig. 1).
Overall, respondents agreed that federal/state coverage
mandates and the growth of quality-driven healthcare
initiatives (that include obesity-related chronic diseases)
would be the most significant contributors to broader
coverage (Fig. 1). The perception that obesity medication
coverage will eventually be mandated by state/federal
governments (and adopted by all payers) emerged as an
overall theme. MCOs and IHSs cited competitor coverage
by other payers and real-world evidence (RWE) pilot
programs as intermediary factors encouraging future re-
imbursement. Not surprisingly, PBMs ranked their support
fourth with physician/patient demand as the lowest lever,
largely because of their mandate to control pharmaceutical
costs. Emergence of the importance surrounding an RWE
requirement for future coverage reflects the growing
ability to easily collect health outcomes and cost data at
the level of the individual providers. Finally, a number of
participants indicated an interest in non-traditional cov-
erage options such as risk-share contracts with pharma-
ceutical manufacturers.
Overall, participants predicted forthcoming access to
anti-obesity medication within a 1- to 5-year time horizon
(Fig. 2).
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5.1 Opportunities: Moving Towards Reimbursement
5.1.1 Federal/State Coverage Mandates
In addition to private insurers, there are government pro-
grams that provide medical and health-related services at
the state and federal levels. Medicare is a nationwide social
program that serves 44 million elderly and disabled people,
whereas Medicaid serves about 40 million low-income
people at the state level [102, 103]. Of note, the most
important lever identified by the stakeholder survey in-
cluded state and federal coverage mandates. At the federal
level, the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) [108] created the
federal prescription drug benefit program Medicare Part D
(effective 1 January 2006), which excluded anti-obesity
drugs from coverage. The MMA did not recite a list of
excluded drugs or classes of drugs; instead, the MMA
identified the exclusions by reference to the Medicaid drug
rebate provisions in the Omnibus Budget Reconciliation
Act of 1990 (OBRA) [109]. Among the drugs ‘‘subject to
restriction’’ were ‘‘Agents when used for anorexia, weight
loss, or weight gain’’. The Centers for Medicare and
Medicaid Services (CMS) further defined this section in
guidance [110] issued on 18 July 2008, which clarified
there was no Part D coverage for ‘‘agents when used
for…weight loss…(even if used for a non-cosmetic pur-
pose, i.e. morbid obesity)’’. However, some private insur-
ance companies with federal contracts to provide Medicare
benefits (known as Medicare Advantage plans) are allowed
to exceed the scope of the Part D-defined benefit; thus,
some Medicare beneficiaries can have covered access to
these drugs, although few have implemented coverage. In
2013, legislative efforts were made to amend the MMA to
include anti-obesity medication: legislation co-sponsored
by a substantial number of members of Congress was in-
troduced in both chambers to allow coverage of weight-
loss medications under Medicare Part D. The Treat and
Reduce Obesity Act of 2013 (H.R. 2415 and S. 1184) [111,
112] amends the MMA to allow coverage of FDA-ap-
proved weight-loss drugs. The bill also attempts to address
the need to expand covered providers’ (i.e., nurse
practitioners, behavioral therapists, others) reimbursement
for intensive BT. Currently, only primary care providers
are eligible for reimbursement, which raises practical
concerns about training and the ability to carve out ade-
quate time within a busy primary care practice. The CMS
considered the impact of BT on practice time and through
coverage constraints created time limits (i.e., 10–15 min).
Unfortunately, experts in BT have raised concerns about
the efficacy of short-term BT interventions [113]. Although
the bills died in December 2014 when the 113th Congress
adjourned, the legislation will be reintroduced in the 114th
Congress. However, as reported by GovTrack (https://
www.govtrack.us/), a government transparency website,
any bill has a very low chance of being enacted in the near
future given the large number of bills introduced each year.
At the state level, programs may elect to cover (either
through state directives or statute) [114] obesity treatments
for Medicaid patients, but they are not required to do so per
OBRA 1990. In addition, state governments legislate,
regulate, and purchase/pay for healthcare for their em-
ployees and retirees. State fiscal pressures and the rising
cost of total healthcare for their citizens has prompted
states to more closely consider the benefits of implement-
ing wellness programs that include coverage of smoking
cessation, stress management, and weight-loss manage-
ment (e.g., New York [115]). In addition, the implemen-
tation of federal healthcare recommendations at the state
level has also affected the coverage offered by commercial
health plans, though not in a uniform manner [116]. Most
states do have health promotion initiatives in place for non-
Medicaid citizens, but no standards of care mandate that
insurance offerings in the private marketplace must cover
weight-loss medicines. Yet, some states have elected to
provide insurance coverage for weight-loss treatments for
their employees and retirees [114]. Whereas at least 23
states, as of 2012, provided wellness programs for their
employees (such as screening for cholesterol, glucose,
blood pressure, and BMI), only a few currently provide
incentives for weight loss and/or coverage of weight-loss
therapies. These states also may provide health coaching
for weight management (e.g., the Kansas HealthQuest
Health and Wellness program).
Fig. 2 Perspectives on
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5.1.2 Measures of Treatment Performance
The next important factor in obesity reimbursement is the
availability of quality measures, which can track obesity
treatment outcomes. There are obesity performance mea-
sures within the Federal ACO MSSP and the Medicare Star
Ratings System for the percentage of patients with a
recorded BMI and the documentation of a follow-up plan
in patients 18 years and older with a BMI outside the
normal range. Also included are additional performance
standards for obesity-associated co-morbidities, such as
diabetes (e.g., glycated hemoglobin control and low density
lipoprotein control), hypertension (e.g., controlling high
blood pressure), and coronary artery disease (e.g., lipid
control). There are financial incentives provided to physi-
cians when a desired performance level is met [117, 118].
Finally, the Healthcare Effectiveness Data and Information
Set (HEDIS), sponsored by the NCQA, is used by various
payers to measure performance on care and service;
HEDIS includes in its measures an adult BMI assessment
and a child/adolescent measure focused on weight assess-
ment and counseling for nutrition and physical activity
[119]. Reporting the results of HEDIS measures allows the
purchasers of healthcare to compare the relative quality of
commercial, Medicaid, and Medicare plans. As new and
evolving obesity treatment approaches gain traction in
clinical practice, additional outcomes and quality measures
related to weight-loss treatment will likely be added to
these quality performance panels. For now, the focus on
BMI and obesity-related co-morbidities is an important
first step in encouraging disease prevention.
5.1.3 Employer Initiatives
Anti-obesity coverage for employees of private companies
is more variable. According to the US Census, in 2013
more than half (i.e., 54 %) of Americans had employment-
based health insurance [120]. Consequently, employers
have enormous influence over insurance coverage. Payer
research indicates that only larger employers who fully
subsidize employees’ healthcare (self-insured employers)
with co-pay offsets borne by the subscriber purchase ad-
ditional coverage outside standard benefits (insurance rid-
ers). Thus, obesity coverage for many Americans is
limited. Payers have indicated that generally an obesity
rider is not directly requested; rather, employers specify
that they believe obesity is a problem in their population
and that they would like information on management op-
tions. Approximately 60 % of current plans (n = 99, based
on large regional and national plans and PBMs) do not
cover anti-obesity medications [68]. Yet, over 50 % of
employers offer wellness programs, largely as a way to
foster employee loyalty, but with little evidence of health
improvements or reduced cost [121]. For pharmaceutical
manufacturers, shifting the employer focus from wellness
offerings to clinical interventions targeting overweight and
obese employees will require real-world studies that ex-
amine the role of structured weight-loss interventions on
cost savings (similar to recent studies, but within employer
groups).
6 Future Directions
The recognition of obesity as a complex disease with
multiple co-morbidities and expensive consequences is
driving research into the development of effective treat-
ment options. Emerging evidence suggests that the best
outcomes derive from multidisciplinary approaches that
utilize a broad range of expertise and varied interventions
with proven synergy [42]. Combination weight-manage-
ment programs coupled with innovative, promising eHealth
programs [122], behavioral incentives [44, 123], and
health-promoting policy decisions [31, 72, 76, 77] should
continue to undergo real-world clinical and economic
evaluation. Historically, the perception of obesity as a
lifestyle concern led payers to limit coverage and physi-
cians to limit prescribing. The scarcity of information
about effective treatment options and clinical outcome
benchmarks resulted in patient-driven demand (or lack of
demand) for certain treatments and unrealistic expectations
of therapy success. Today, however, the consequences of
obesity are understood as both clinically and economically
relevant, and obesity itself is no longer considered merely a
lifestyle issue. As data emerge on the cost benefit of
medical weight management, barriers to managed care
coverage will likely decline.
Further research, particularly focusing on outcomes and
economic benefits in real-world settings, needs to be con-
ducted on all proposed approaches, whether primary pre-
vention, lifestyle- or behavior-focused clinical
interventions, surgical or pharmacologic interventions, or a
combination. The creation of quality metrics and data-
driven healthcare community practice will formulate this
effort. Other innovative approaches that demonstrate value,
such as risk- or outcomes-based contracting between in-
surers and manufacturers, may help drive innovation and
hasten the evolution of the value proposition needed to
persuade payers, employers, providers, and patients of the
benefits of pharmacotherapy.
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